We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis

By LabMedica International staff writers
Posted on 05 Aug 2026

Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure. More...

Prolonged antibiotic use can alter the airway microbiome, promote antimicrobial resistance, and complicate efforts to select targeted therapies. Rapid and accurate identification of pathogens and resistance determinants is therefore essential for effective clinical management. New findings highlight how DNA sequencing can improve the detection and characterization of respiratory infections, supporting more precise treatment decisions.

Researchers at Flinders University examined the use of DNA sequencing reads to more accurately identify microbial infections in cystic fibrosis and other respiratory diseases. The approach is described in a study published in Clinical Microbiology Reviews on August 3, 2026, and is considered in the context of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies, which have transformed the course of the disease for many patients.

The researchers emphasize that comprehensive microbial surveillance using sequencing technologies will be important for understanding how CFTR modulators reshape the airway microbiome over time. By improving diagnostic precision and providing greater insight into pathogens and antimicrobial resistance, sequencing-based approaches could help clinicians reduce the risks associated with extensive antibiotic exposure and tailor treatment more effectively.

The technology centers on respiratory metagenomic sequencing and related read-level analyses, enabling researchers to characterize entire airway microbial communities rather than search for individual pathogens. According to the institution, sequencing can track shifts in the microbiome, detect infections more rapidly than traditional laboratory methods, and identify antimicrobial resistance.

The approach can also reveal community composition and diversity, strain-level variation, antimicrobial resistance genes, virulence determinants, and microbial metabolic functions. By analyzing these features directly from clinical samples, sequencing-based methods may accelerate organism identification and help guide more targeted antimicrobial treatment.

Potential implementation pathways include portable sequencing devices, some no larger than a cellphone and connected to a laptop, that could bring rapid testing into hospitals as well as remote and rural settings. Although these tools are already being adopted in select care environments, the authors note that further evaluation is needed before they can be integrated into routine clinical practice in Australia.

The technology may also have applications beyond cystic fibrosis, supporting earlier diagnosis and more precise treatment across a range of respiratory and other microbially driven conditions. Overall, the review highlights the potential of rapid sequencing workflows to enable real-time pathogen surveillance and more personalized antimicrobial strategies.

“DNA sequencing is transforming how we diagnose and manage infections, revealing entire microbial communities instead of single pathogens and paving the way for faster, more precise and personalized treatment,” said Rob Edwards, Professor of Bioinformatics at Flinders University.

“Respiratory metagenomic sequencing is already being introduced into intensive care units in the UK to provide faster diagnosis of severe respiratory infections and guide antimicrobial therapy,” said Dr. Jessica Carlson-Jones, research associate at the Flinders Accelerator for Microbiome Exploration (FAME).

Related Links
Flinders University 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: iStock

AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health

Advances in molecular diagnostics are creating new opportunities to improve the detection of sexually transmitted infections, identify antibiotic resistance, and assess cancer recurrence risk in women.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.